“2025 marked the most successful year in Esperion’s (ESPR) history, driven by exceptional execution across our U.S. commercial strategy, expanded global reach and performance, and significant progress across our pipeline – all while delivering meaningful growth in our cardiovascular franchise and strengthening our financial position. These achievements set the stage for something far bigger: Vision 2040. This bold roadmap reflects our commitment to transform Esperion into a multi-product, sustainable, innovation-driven global pharmaceutical company that not only leads in cardiovascular disease prevention but also addresses a broader spectrum of unmet medical needs,” said Sheldon Koenig, Chief Executive Officer of Esperion.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion (ESPR): Growing Global Guideline Endorsements and Regulatory Milestones for Bempedoic Acid Support Buy Rating and $16 Target
- Esperion’s bempedoic acid receives recommendation in 2025 ACC statement
- Largest borrow rate increases among liquid names
- Midday Fly By: Alphabet continues ascent, fueled by AI optimism
- Esperion initiated with an Overweight at Piper Sandler